Most are using maintenance therapy to buy time
Regarding patients’ expectations when undergoing maintenance therapy, 45% of the participants with primary cancer and 50% with recurrent cancer responded by stating that they hoped maintenance therapy could help by at least buying them some time. In other words, they anticipated prevention of the progression of cancer for around 6 months. This anticipation notion was similar in both younger and older patients with primary and recurrent cancer. More than 30% of the participants with primary cancer and 20% with recurrent cancer expected maintenance therapy to help delay cancer recurrence by 6-12 months, while less than 5% of both groups expected delay in the progression of cancer by 2-3 years.